为应对全球日益严峻的肥胖健康挑战,近日,世界卫生组织发布了首个关于将胰高血糖素样肽-1(GLP-1)类药物用于治疗肥胖的全球指南。肥胖症是一种慢性复发性疾病,据联合国新闻官网消息,目前,全球已有超过10亿人受肥胖困扰。2024年肥胖相关死亡人数高达370万。若不采取果断行动,预计到2030年,肥胖人数还将翻倍。世卫组织将成人体重指数(BMI)≥30定义为肥胖。GLP-1受体激动剂是一类可降低血糖、...
Source Link为应对全球日益严峻的肥胖健康挑战,近日,世界卫生组织发布了首个关于将胰高血糖素样肽-1(GLP-1)类药物用于治疗肥胖的全球指南。肥胖症是一种慢性复发性疾病,据联合国新闻官网消息,目前,全球已有超过10亿人受肥胖困扰。2024年肥胖相关死亡人数高达370万。若不采取果断行动,预计到2030年,肥胖人数还将翻倍。世卫组织将成人体重指数(BMI)≥30定义为肥胖。GLP-1受体激动剂是一类可降低血糖、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.